Sobi, Innate Pharma License Lacutamab for T-Cell Lymphoma Development

In-house counsel at biopharmaceutical firms with oncology pipeline assets must track this licensing structure, which sets a precedent for splitting late-stage trial and commercialization rights to de-risk drug development.